819 results on '"Quesnel, Bruno"'
Search Results
2. Deciphering genetic and nongenetic factors underlying tumour dormancy: insights from multiomics analysis of two syngeneic MRD models of melanoma and leukemia
3. Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors
4. Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
5. MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma
6. Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation
7. Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents
8. Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
9. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
10. TRPC3 shapes the ER-mitochondria Ca2+ transfer characterizing tumour-promoting senescence
11. Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
12. MYC dependency in GLS1 and NAMPT is a therapeutic vulnerability in multiple myeloma
13. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
14. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia
15. Familial myeloid malignancies with germline TET2 mutation
16. Induction of AML cell differentiation using HOXA9/DNA binding inhibitors as a potential therapeutic option for HOXA9‐dependent AML.
17. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes
18. Tumor Necrosis Factor-Alpha/Tumor Necrosis Factor-Alpha Receptor 1 Signaling Pathway Leads to Thymocytes' Cell Death by Necroptosis in a Mouse Model of Acute Myeloid Leukemia
19. Supplemental Table 3 Characteristics of patients with WM according to CXC4 mutation status from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
20. Supplemental Table 1 Gene expression profilling from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
21. Supplementary Table 1, Supplementary Figures 1-4 from TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
22. List of pathways analyzed for GSEA from Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
23. Supplementary Data Figure Legends from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
24. Supplementary Figure 5 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
25. Supplementary Data Figures 1-4 from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
26. Supplementary Figure 6 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
27. Data from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
28. Supplementary Figure 3 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
29. Supplementary Table 1 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
30. Data from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
31. Supplementary Figure 1 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
32. Supplementary Figure 2 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
33. Supplementary Figure 4 from Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1
34. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
35. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group
36. Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology
37. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia
38. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
39. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein
40. Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG ‐asparaginase
41. Tumor Dormancy: Long-Term Survival in a Hostile Environment
42. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors
43. Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
44. Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
45. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)
46. MYD88 L265P mutation in Waldenstrom macroglobulinemia
47. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification
48. Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis
49. Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial
50. Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.